Overview

A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101

Status:
Recruiting
Trial end date:
2022-03-31
Target enrollment:
Participant gender:
Summary
Safety and tolerability study of 2 concentrations of QLS-101 for adult subjects with Sturge Weber Syndrome (SWS)-related glaucoma due to elevated episcleral venous pressure (EVP).
Phase:
Phase 2
Details
Lead Sponsor:
Qlaris Bio, Inc.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions